Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

SPINEWAY :Signature of a distribution agreement in Australia 1st Mont-Blanc implants

SPINEWAY
Posted on: 05 Apr 17

Press release                                                                                                                                                                               Ecully, 5 April 2017

Signature of a distribution agreement in Australia
1 st Mont-Blanc implants

Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), announces the signature of a contract with an Australian distributor for the sale of its implants and instruments in Oceania.

The distribution agreement follows the approval of the Group's flagship lines and reinforces Spineway's international coverage.

The distributor, based in Sydney, specializes in orthopedics and is extremely experienced with the spine. It will sell Spineway's Mont-Blanc, TwinPeaks, Kili, Ayers Rock and Blue Mountain lines. Its salesforce and distribution network will allow the Group to cover Sydney and Australia's other major cities.

The first surgeries using Mont-Blanc implants have already taken place and were very successful.

Spineway thus establishes its know-how in overseas exports and should see its sales increase steadily in this new geographic area.

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLAN FOR SMES)
Find out all about Spineway at www.spineway.com

Next communication:
2016 Annual Results - 26 April 2017, after market closes

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) - Talent INPI award (2015).
ISIN code: FR0011398874 - ALSPW     

Contacts:

Investor Relations
David Siegrist - Finance Director
Tel : +33 (0)4 72 77 01 52
finance.dsg@spineway.com
Financial Communication
Jérôme Gacoin / Solène Kennis
Tel: +33 (0)1 75 77 54 68
skennis@aelium.fr
Distribution agreement in Australia


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: SPINEWAY via GlobeNewswire
HUG#2094094
GlobeNewswire
globenewswire.com

Last updated on: 06/04/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.